Key corporate developments and strategic deals marked the biotech and pharma landscape. Bayer extended CEO Bill Anderson's contract through March 2029 to continue transformation efforts. Sino Biopharmaceutical acquired Lanova Medicines for up to $951 million, consolidating oncology portfolios. AbbVie licensed Ichnos Glenmark Innovation's trispecific T-cell engager ISB 2001 for over $1.9 billion potential value in multiple myeloma. Waters expanded its clinical diagnostics footprint with a $17.5 billion acquisition of Becton Dickinson’s biosciences and diagnostics business. Labcorp announced competition moves in health testing. Meanwhile, leadership transitions occurred at PureTech Health and consumer healthcare firm Kenvue amid strategic reviews.